These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 9058819)
1. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation. Cayeux S; Richter G; Noffz G; Dörken B; Blankenstein T J Immunol; 1997 Mar; 158(6):2834-41. PubMed ID: 9058819 [TBL] [Abstract][Full Text] [Related]
2. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo. Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016 [TBL] [Abstract][Full Text] [Related]
3. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency. Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574 [TBL] [Abstract][Full Text] [Related]
4. Decreased generation of anti-tumor immunity after intrasplenic immunization. Cayeux S; Qin Z; Dörken B; Blankenstein T Eur J Immunol; 2001 May; 31(5):1392-9. PubMed ID: 11465096 [TBL] [Abstract][Full Text] [Related]
5. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF. Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934 [TBL] [Abstract][Full Text] [Related]
6. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. Levitsky HI; Montgomery J; Ahmadzadeh M; Staveley-O'Carroll K; Guarnieri F; Longo DL; Kwak LW J Immunol; 1996 May; 156(10):3858-65. PubMed ID: 8621924 [TBL] [Abstract][Full Text] [Related]
7. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Cayeux S; Beck C; Aicher A; Dörken B; Blankenstein T Eur J Immunol; 1995 Aug; 25(8):2325-31. PubMed ID: 7545119 [TBL] [Abstract][Full Text] [Related]
8. Generation of tumor-specific cytotoxic T lymphocyte and prolongation of the survival of tumor-bearing mice using interleukin-18-secreting fibroblasts loaded with an epitope peptide. Chung SW; Cohen EP; Kim TS Vaccine; 2004 Jun; 22(20):2547-57. PubMed ID: 15193380 [TBL] [Abstract][Full Text] [Related]
9. Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice. Kim TS; Lee BC; Kim E; Cho D; Cohen EP Vaccine; 2008 Nov; 26(47):5928-34. PubMed ID: 18793691 [TBL] [Abstract][Full Text] [Related]
10. Co-modification of IL-2-TNF alpha fusion gene and B7.1 gene to murine breast tumor cells leads to improved tumor rejection and vaccine effect. Liu X; Zhang L; Zhang M; Ma Y; Xu X; Cai Y Chin Med J (Engl); 2000 Feb; 113(2):167-71. PubMed ID: 11775545 [TBL] [Abstract][Full Text] [Related]
11. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
12. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma. Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650 [TBL] [Abstract][Full Text] [Related]
13. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells. Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497 [TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes. Ali SA; McLean CS; Boursnell ME; Martin G; Holmes CL; Reeder S; Entwisle C; Blakeley DM; Shields JG; Todryk S; Vile R; Robins RA; Rees RC Cancer Res; 2000 Mar; 60(6):1663-70. PubMed ID: 10749137 [TBL] [Abstract][Full Text] [Related]
15. DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors. Schirmbeck R; Böhm W; Reimann J J Immunol; 1996 Oct; 157(8):3550-8. PubMed ID: 8871655 [TBL] [Abstract][Full Text] [Related]
16. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Cavallo F; Martin-Fontecha A; Bellone M; Heltai S; Gatti E; Tornaghi P; Freschi M; Forni G; Dellabona P; Casorati G Eur J Immunol; 1995 May; 25(5):1154-62. PubMed ID: 7539748 [TBL] [Abstract][Full Text] [Related]
17. The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus. Rosato A; Dalla Santa S; Zoso A; Giacomelli S; Milan G; Macino B; Tosello V; Dellabona P; Lollini PL; De Giovanni C; Zanovello P Cancer Res; 2003 May; 63(9):2158-63. PubMed ID: 12727834 [TBL] [Abstract][Full Text] [Related]
18. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase. LaTemple DC; Abrams JT; Zhang SY; Galili U Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604 [TBL] [Abstract][Full Text] [Related]
19. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen. Tüting T; Gambotto A; Robbins PD; Storkus WJ; DeLeo AB Gene Ther; 1999 Apr; 6(4):629-36. PubMed ID: 10476222 [TBL] [Abstract][Full Text] [Related]
20. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. Guinn BA; DeBenedette MA; Watts TH; Berinstein NL J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]